Clinical Utility of Monitoring for Human Herpesvirus-6 (HHV-6) and Human Herpesvirus-7 (HHV-7) After Liver Transplant

Phase 4

Completed

Brief Summary: Human herpesvirus-6 (HHV-6) and -7 (HHV-7) infections are common after transplantation. Such infections may predispose transplant patients to other infections, contribute to a recurrence of hepatitis C virus, and affect rejection and function of the transplanted liver. Given the significant clinical impact of these viruses, routine laboratory monitoring may be beneficial by identifying patients who have persistent or high levels of infection. In these patients, immunosuppressive medications could be adjusted, or antiviral medications administered. There are currently no randomized trials that address this important question. This prospective, randomized trial will analyze whether routine laboratory monitoring for HHV-6 and -7 is clinically useful, and whether it would improve overall outcomes in transplant recipients.

Recruitment & Eligibility

Inclusion Criteria

Male or female patients who fulfill the following criteria are eligible for inclusion:
- Recipients of a liver transplant
- Able to give written informed consent
- Are willing and able to comply with the protocol
- Age >= 18 years

Exclusion Criteria

The following patients are not eligible for inclusion in the study:

Primary Outcome Measures

Name	Time	Method
Adverse clinic events due to direct or indirect effects.

Secondary Outcome Measures

Name	Time	Method

Receive instant email notifications about changes in this clinical trial

Receive instant email notifications about changes in this clinical trial